Warren K S, Siongok T K, Ouma J H, Houser H B
Lancet. 1978 Feb 18;1(8060):352-4. doi: 10.1016/s0140-6736(78)91080-2.
The recommended doses of the drugs now used to cure schistosomiasis mansoni may be associated with toxic side-effects. Since Schistosoma mansoni does not multiply in the human host and the disease seems to be closely associated with the intensity of infection, it may not be necessary to use 100% lethal antischistosomal doses, particularly in endemic areas. A dose-response to the antischistosomal drug, hycanthone was established for three different doses in 169 patients with heavy S. mansoni infections in the Machakos district of Kenya. The highest dose used (1.5 mg/kg or half the recommended package-insert dose) resulted in a 96% decrease in egg output (equivalent ot death of the worms); 0.75 mg/kg in an 85% decrease; and 0.375 mg/kg in an 11% decrease one month after treatment. In contrast to the vomiting common with the package-insert dose (3.0 mg/kg), there were no side-effects with any of the lower doses.
目前用于治疗曼氏血吸虫病的药物推荐剂量可能会伴有毒副作用。由于曼氏血吸虫不在人类宿主体内繁殖,且该疾病似乎与感染强度密切相关,因此可能无需使用100%致死剂量的抗血吸虫药物,尤其是在流行地区。在肯尼亚马查科斯区,对169例重度曼氏血吸虫感染患者使用三种不同剂量的抗血吸虫药物海恩酮建立了剂量反应关系。所用最高剂量(1.5毫克/千克或推荐包装说明书剂量的一半)使虫卵排出量减少了96%(相当于虫体死亡);0.75毫克/千克使虫卵排出量减少了85%;0.375毫克/千克在治疗后一个月使虫卵排出量减少了11%。与包装说明书剂量(3.0毫克/千克)常见的呕吐现象不同,较低剂量均未产生副作用。